-
The first case of formaldehyde release detection of ultra-conventional flooring products was reported
Time of Update: 2021-02-27
China Paint Network News: At present, the relevant state departments on the floor products formaldehyde limit release value of the detection, is in the standard environment of 18 degrees C to 22 degrees C, and in daily life, room temperature
-
Keytruda and Lenvima Phase 3 Clinical: Efficacy beats Schoinidini!
Time of Update: 2021-02-27
kinase inhibitor Lenvima First-line treatment of patients with advanced renal cell carcinoma (RCC) and comparison with the Lenvima®Ivimos and sunitinib programmes. results showed that Keytruda and Lenvima showed statistically significant
-
GSK intends to sell its nutrition business to Lihua for $3 billion
Time of Update: 2021-02-27
GlaxoSmithKline's nutrition business includes the popular Horlicks malt beverage brand in India, and Horlicks' product line, which is sold mainly in Asia, is a nutritional supplement to the children's diet.
-
All over the "ignition" Kangmei Pharmaceuticals half a year to throw more than 3 billion
Time of Update: 2021-02-27
that the construction of this project is mainly to expand the company's Chinese medicine tablets, health food production capacity, improve the company's logistics services capacity, give full play to the company's entire industrial chain advantages
-
The Kunming Plant of the Chinese Academy of Sciences cultivates 3 new varieties of spring flowers
Time of Update: 2021-02-27
Bai Shui Zixiared pink good people gold powder good people Recently, Kunming plants in the very small population of wild plants integrated protection team to cultivate 3 new varieties of spring flowers
-
" combination Opdivo-Cabometyx Phase 3 Clinical Beats Schoinini!
Time of Update: 2021-02-27
Cancer Symposium (ASCO-GU 2021) on March 13, confirm the clinical significance of the first-line treatment of advanced renal cell carcinoma (R) CC) compared to the first-line standard care drug Suttent (Sotan, generic name: sunitinib, shonithini
-
First-line immunotherapy for head and neck cancer! AstraZenecom anti-PD-L1 therapy Imfinzi (Infinfan) Phase 3 clinical failure!
Time of Update: 2021-02-27
